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S U M M A R Y
Background: Limited data are available on hepatic steatosis (HS) in HIV patients who are not infected
with hepatitis C virus (HCV). The aims of this study were to assess the prevalence of HS and its risk factors
in HIV patients with and without HCV infection, and to evaluate whether HS correlates with advanced
liver ﬁbrosis and/or cardiovascular disease risk.
Methods: Fifty-seven HIV mono-infected and 61 HIV/HCV co-infected patients were enrolled
consecutively. All patients underwent liver ultrasound and transient elastography. The main parameters
of liver function, HIV and HCV viral loads, CD4+ cell counts, and data on highly active antiretroviral
therapy (HAART) were recorded. Cardiovascular disease risk was evaluated using the 10-year
Framingham risk score.
Results: HS prevalence in the whole HIV population was 53% (54% in mono-infected patients and 51% in
co-infected patients). HS was associated with lipodystrophy and triglyceride values (p < 0.0001),
metabolic syndrome (p < 0.0004), and total cholesterol levels (p < 0.001) in both HIV groups. In HIV
mono-infected patients, HS was linked with HAART exposure of >1 year (p < 0.01). By multivariate
analysis, only triglyceride levels (p < 0.02) and Framingham risk score (p < 0.05) were independently
associated with HS in both HIV groups. No correlation was observed between HS and advanced liver
ﬁbrosis, measured by transient elastography.
Conclusions: HS was common in HIV patients, occurring in about half of the population. HS was found to
be linked with the Framingham risk score, but was not correlated with advanced liver ﬁbrosis. We
suggest that in our HIV population with HS, the burden of cardiovascular disease risk is greater than that
of liver disease progression.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hepatic steatosis (HS) includes a wide spectrum of conditions,
characterized by the accumulation of lipid droplets within the
cytoplasm of hepatocytes, ranging from fatty inﬁltration to
steatohepatitis. Patients with steatohepatitis are at risk of
progressive ﬁbrosis, cirrhosis, and hepatocellular carcinoma.1
Before the era of highly-active antiretroviral therapy (HAART),
HS prevalence in HIV-infected patients was about 30%,2 similar to
the general population.3 HIV-infected patients may be at
particular risk of HS, as HIV infection per se can result in fat
deposition in the liver. In this respect, the chronic inﬂammatory
state induced by the virus itself in patients with active infection, in* Corresponding author. Tel.: +39 (0)91 6552991; fax: +39 (0)91 6552948.
E-mail address: gmontal@unipa.it (G. Montalto).
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doi:10.1016/j.ijid.2012.01.011particular the increase in levels of the pro-inﬂammatory cytokines
such as tumor necrosis factor-alpha (TNF-a), may lead to an
increased synthesis of triglycerides by different mechanisms and,
as a consequence, to their accumulation in fat droplets within the
cytoplasm of hepatocytes.4,5 In addition, new evidence shows that
HIV-related microbial translocation may promote hepatic dam-
age due to immune activation.6 Little is known about the
prevalence of HS and its risk factors among patients with HIV
infection alone in the post-HAART era. Controversy remains
regarding the effects of HAART on HS pathogenesis.5 Other
coexisting morbidities, such as obesity,7 diabetes mellitus,8 and
alcohol intake, may cause steatogenesis in HIV patients, as is
the case in the general population.6 Also hepatitis C virus (HCV)
may induce HS via several molecular mechanisms. Despite
this evidence, many divergences persist regarding HS prevalence
in HIV/HCV co-infected patients, with values ranging from 23%
to 72%.9ses. Published by Elsevier Ltd. All rights reserved.
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(NAFLD) and its relationship with cardiovascular disease (CVD)
risk in the general population has increased. Although Ghouri
et al.10 stated that evidence for this association is weak, there is
currently growing clinical evidence supporting the strong associa-
tion between NAFLD and CVD risk.11 To date, few data are available
on the link between HS and CVD risk in the HIV population.12
Liver biopsy is the best diagnostic tool for the diagnosis of HS.
However, it is an invasive technique and may result in sampling
errors,13–15 therefore it is not suitable for routine HS assessment.
Ultrasonography, because of its low cost, non-invasiveness, and
widespread availability, is accepted as an initial screening tool for
HS16,17 and is the most frequently used technique for HS
diagnosis.18 Thus, the aims of this study were to assess the
prevalence of HS and its main risk factors in a group of HIV mono-
infected and HIV/HCV co-infected patients. In addition, we sought
to evaluate whether steatosis is correlated with advanced liver
ﬁbrosis, measured as liver stiffness (LS), and CVD risk, evaluated
with the 10-year Framingham risk score.
2. Patients and methods
2.1. Study population
The study population consisted of HIV mono-infected and HIV/
HCV co-infected patients enrolled consecutively from January
2009 to August 2010, who were followed-up prospectively at our
AIDS center. All of these patients underwent ultrasound (US) and
transient elastography of the liver.
Patients with acute liver events, hepatocellular carcinoma,
chronic hepatitis B, decompensated cirrhosis, a body mass index
(BMI) >30 kg/m2, and/or without LS evaluation were excluded
from the study.
Information on age, gender, risk factors for HCV and HIV
infections, duration of antiretroviral therapy (ART), and exposure
to non-nucleoside reverse-transcriptase inhibitors (NNRTI)/nucle-
oside reverse-transcriptase inhibitors (NRTI), protease inhibitors
(PI), and speciﬁc dideoxynucleosides (d-drugs) were all recorded in
a database designed for this study. HAART exposure was graded 0
(no HAART) to 2 (1: <1 year; 2: >1 year).
Alcohol intake >20 g/day either at the time of the study or in the
past was recorded through patient interviews. BMI was calculated
as weight (in kg) divided by height squared (m2). Diabetes mellitus
and impaired fasting glucose (IFG) were deﬁned according to the
Expert Committee on the Diagnosis and Classiﬁcation of Diabetes
Mellitus criteria.19 Diabetes and IFG were analyzed together
because of the small number of patients. Smoking status was also
evaluated. Metabolic syndrome was diagnosed according to the
National Cholesterol Education Program deﬁnition.20 The 10-year
CVD risk was assessed in HIV mono-infected and co-infected
patients by applying the Framingham risk score.21 Lipodystrophy
was deﬁned as the presence of body fat changes, sub-cutaneous fat
loss, and/or increased waist or buffalo hump, recognized by the
patients and conﬁrmed by the physicians.22
CD4 T-cell counts (most recent value and nadir) and plasma
HIV-RNA levels were assessed in all HIV patients. In the HCV-
infected patients, HCV genotype and plasma HCV-RNA levels were
also recorded. Moreover, baseline complete blood cell count,
alanine aminotransferase (ALT), aspartate aminotransferase (AST),
total cholesterol, high-density lipoprotein (HDL) cholesterol, low-
density lipoprotein (LDL) cholesterol, triglycerides, and glycemia,
were measured in the total study population. The plasma
concentration ratio of triglycerides to HDL cholesterol (TG/HDL-
C ratio) was also calculated as a surrogate marker of insulin
resistance.23 All the blood tests at baseline were performed on
samples from fasting patients.The study protocol conformed to the ethical guidelines of the
1975 Declaration of Helsinki.
2.2. Ultrasound assessment
Liver US was performed in the morning, after fasting for at least
10 h, by a single operator (MS), using a real-time Philips 5000 HDI
apparatus with a 2–5 MHz convex multi-frequency probe.
The hepatic parenchyma echo-pattern was scored as: (1)
normal (N), when echoes were homogeneously distributed and
liver echogenicity was not increased in relation to the parenchyma
of the right kidney; (2) ‘bright liver’ pattern (BL), characterized by
numerous ﬁne-packed, uniformly distributed echoes of high
amplitude and increased echogenicity when compared to the
parenchyma of the right kidney; (3) coarse pattern (C), represented
by the presence of non-homogeneous, coarse, irregular echoes,
without posterior beam attenuation;24 and (4) coarse nodular
pattern (CN), when multiple, distinct, weakly hypoechoic nodules
(<6 mm in diameter) were widely spread over the liver
parenchyma.25
BL is the hepatic echo-pattern characteristic of HS. BL severity
was scored as: grade 1 (mild steatosis), characterized by increased
echogenicity; grade 2 (moderate steatosis), accompanied by
increased echogenicity and posterior beam attenuation with
slightly impaired visualization of the intrahepatic vessels and
diaphragm; grade 3 (severe steatosis), with a marked increase in
echogenicity and marked posterior beam attenuation resulting in
failure to demonstrate the intrahepatic vessels, diaphragm, and
posterior right lobe of the liver.26
2.3. Liver ﬁbrosis assessment
Liver ﬁbrosis was assessed by a single certiﬁed operator
(trained by the manufacturer) using transient elastography
(FibroScan1; EchoSens, Paris, France), as previously described.27
Transient elastography provides an assessment of liver stiffness
(LS) expressed in units of kPa.
Advanced liver ﬁbrosis (severe ﬁbrosis and cirrhosis) was
deﬁned as a median LS of 9.5 kPa. This cut-off value is strongly
correlated with a Metavir score of F3 in HIV/HCV co-infected
patients.28
2.4. Statistical analysis
A descriptive analysis was carried out for all the clinical and
demographic variables. When the data distribution was Gaussian,
values were expressed as mean  standard deviation and their
differences were calculated using the Student’s t-test. Otherwise, data
were expressed as median and range and analyzed with the Mann–
Whitney U-test. Fisher’s exact test and the Chi-square test, Mantel–
Haenszel Chi-square test, Spearman’s rank correlation, and Pearson’s
correlation were used where appropriate. Multiple logistic regression
analysis was performed to estimate the independence of the
association between BL and variables signiﬁcant on univariate
analysis. Variables contributing signiﬁcantly to the ﬁt of the logistic
equation were then selected by a step-wise procedure. A p-value of
<0.05 was considered signiﬁcant.
All analyses were performed using the SPSS software package
(version 13.0; Chicago, IL, USA).
3. Results
3.1. Study population
One hundred and twenty-two patients were evaluated during
the study period. An LS measurement was not obtained for four
Table 1
Baseline clinical and demographic features
Characteristics HIV (n = 57) HIV/HCV
(n = 61)
p-Value
Age (years), mean  SD 45  9.0 45.2  5.3 NS
Male gender, n (%) 38 (67) 48 (79) NS
BMI (kg/m2), mean  SD 23.6  3.2 23  2.9 NS
Patients under HAART, n (%) 46 (81) 53 (87) NS
Previous ART (years), median
(range)
7 (0.1–17) 10 (0.1–21) <0.03
Alcohol, n (%) 6 (11) 6 (10) NS
IFG/diabetes, n (%) 2 (4) 14 (23) <0.002
Lipodystrophy, n (%) 28 (49) 42 (69) <0.004
Metabolic syndrome, n (%) 16 (28) 12 (20) NS
Framingham risk score >10%,
n (%)
14 (25) 7 (11) NS
HCV, hepatitis C virus; SD, standard deviation; BMI, body mass index; HAART,
highly active antiretroviral therapy; ART, antiretroviral therapy; IFG, impaired
fasting glucose; NS, not signiﬁcant.
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patients were eligible for inclusion in the study. Fifty-seven of the
patients were HIV mono-infected and 61 were HIV/HCV co-
infected.
Patient baseline characteristics at the time of US and LS
measurement are shown in Table 1. No signiﬁcant difference was
found in mean age or BMI values between the HIV mono-infected
and co-infected patients. At the time of US and LS measurement,
most of the HIV mono-infected (n = 46; 81%) and HIV/HCV co-
infected (n = 53; 87%) patients were on HAART. The duration of ART
exposure was signiﬁcantly longer in the co-infected than in the HIV
mono-infected patients (p < 0.03). IFG/diabetes was signiﬁcantly
more frequent in the co-infected than in the HIV mono-infected
patients (p < 0.002), as was lipodystrophy (p < 0.004). No associa-
tion was found between the number of HIV mono-infected and co-
infected patients and metabolic syndrome.
Table 2 shows the main hematological and virological
parameters in the study population. All of the HCV co-infectedTable 2
Main hematological and virological characteristics
Characteristics HIV (n = 57) HIV/HCV (n = 61) p-Value
ALT U/l, median (IQR) 23 (7–117) 54 (17–280) <0.0001
AST U/l, median (IQR) 23 (11–56) 41 (17–281) <0.0001
Total cholesterol
(mg/dl), mean  SD
207  49 167.3  41.6 <0.0001
HDL cholesterol
(mg/dl), mean  SD
42  10.5 43.8  16.4 NS
LDL cholesterol
(mg/dl), mean  SD
132.7  40.6 95.2  35.3 <0.0001
Triglycerides
(mg/dl), median (IQR)
182 (49–615) 117 (50–614) <0.0001
TG/HDL-C ratio,
median (IQR)
3.9 (0.7–22.8) 3 (1–20) NS
Genotypea
Genotype 3, n (%) - 19 (31) -
Genotype 1 (n, %) - 29 (48) -
Genotype 2, 4 - 8 (13) -
HCV-RNA (IU/ml)
>700 000, n (%)
- 44 (72) -
HIV-RNA <47
copies/ml, n (%)
33 (58) 41 (67) NS
CD4+ count (cells/ml),
median (IQR)
447 (35–1093) 422 (35–1208) NS
CD4+ <200
cells/ml, n (%)
33 (58) 41 (67) NS
HCV, hepatitis C virus; ALT, alanine aminotransferase; AST, aspartate aminotrans-
ferase; IQR, interquartile range; SD, standard deviation; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; TG/HDL-C ratio, triglycerides to high-
density lipoprotein cholesterol ratio; NS, not signiﬁcant.
a Genotypes were not known for ﬁve patients, because of the non-eligibility of
patients for ART.patients had detectable HCV-RNA and 44 patients had HCV-RNA
>700 000 IU/ml. Serum ALT and AST levels were signiﬁcantly
higher in the co-infected than in the HIV mono-infected patients
(p < 0.0001). Total cholesterol, LDL cholesterol, and triglyceride
levels were higher in the HIV mono-infected than in the co-
infected patients (p < 0.0001).
3.2. Prevalence of BL and association with risk factors
The BL pattern was present in 62 (53%) patients in the total HIV
population, of which 31/57 (54%) were HIV mono-infected and 31/
61 (51%) were HIV/HCV co-infected (p = not signiﬁcant). BL of
grade 2/3 was present in only in 10 (16%) patients (seven HIV
mono-infected and three co-infected).
Table 3 shows the associations between BL and risk factors
analyzed in the whole population by univariate analysis. BL was
associated with higher BMI (p < 0.05), lipodystrophy (p < 0.0001),
and metabolic syndrome (p < 0.0004). Higher values of total
cholesterol (p < 0.001), triglycerides and TG/HDL-C ratio
(p < 0.0001) were also associated with BL.
In addition, undetectable HIV-RNA (p < 0.03) and CD4+ nadir
<200 cells/ml (p < 0.03) were associated with BL. Although the
levels of HIV-RNA were higher in patients with BL than in those
without BL (6500 (interquartile range 50–1 110 000) vs. 1750
(interquartile range 60–700 000) copies/ml), the difference was
not signiﬁcant (z = 0.47; p = not signiﬁcant). The correlation
between the severity of BL and HIV-RNA levels was not signiﬁcant
either (rho = 0.07; p = not signiﬁcant).
No signiﬁcant difference was found in cumulative ART exposure
between patients with and without BL. Using the HAART exposure
score, we found that HAART exposure for more than 1 year was
signiﬁcantly associated with BL in both the total HIV population
(p < 0.02) and the HIV mono-infected patients (p < 0.01) (Tables 3
and 4). No statistical difference was found when the patients with
or without BL in both HIV groups were analyzed for exposure >1
year to the single classes of antiretroviral drugs and speciﬁcally d-
drugs (Tables 3 and 4). Only the association between BL and NNRTI
exposure >1 year was close to statistical signiﬁcance (p = 0.07).
Among the HIV mono-infected patients, BL was associated with
lipodystrophy, metabolic syndrome (p < 0.02), and higher values of
total cholesterol (p < 0.003), triglycerides (p < 0.002), ALT (p < 0.04),
and TG/HDL-C ratio (p < 0.001) (Table 4). Furthermore, BL was
associated with undetectable HIV-RNA (p < 0.001), CD4+ nadir < 200
cells/ml, and HAART exposure >1 year (p < 0.01) (Table 4).
In the HIV/HCV co-infected patients, lipodystrophy (p < 0.003),
metabolic syndrome (p < 0.03), and higher values of total
cholesterol (p < 0.04), triglycerides (p < 0.02), and TG/HDL-C ratio
(p < 0.05) were associated with BL (Table 4).
3.3. Association between BL and other studied parameters (LS and
Framingham risk score)
No association was observed between BL and liver ﬁbrosis or
between BL grading and advanced liver ﬁbrosis (measured as LS).
Figure 1 shows the correlation between the hepatic parenchyma
echo-patterns and LS. Increasing values of LS were correlated with
an advanced liver ﬁbrosis ultrasound echo-pattern (coarse and
coarse nodular echo-pattern) (rho = 0.24; p < 0.02).
Framingham risk score values were signiﬁcantly correlated
with BL in both the HIV mono-infected and HIV/HCV co-infected
patients (rho = 0.3; p < 0.004).
3.4. Factors associated with BL on multivariate analysis
Among all the variables signiﬁcantly associated with BL on
univariate analysis, only triglyceride levels (b = 0.15; odds ratio
Table 3
Relationship between bright liver echo-pattern (BL negative/BL positive) and studied variables in the whole HIV population
Variables Total HIV Univariate analysis
BL neg (n = 56) BL pos (n = 62) p-Value
Age (years), mean  SD 44.2  8.8 45.8  5.5 NS
BMI (kg/m2), mean  SD 22.7  2.9 23.8  3.2 0.05
Alcohol use, n (%) 3 (5) 10 (16) NS
Lipodystrophy, n (%) 23 (41) 47 (76) 0.0001
Metabolic syndrome, n (%) 5 (9) 23 (37) 0.0004
Total cholesterol (mg/dl), mean  SD 170  39 201  53 0.001
HDL cholesterol (mg/dl), mean  SD 44.7  14 41.4  13.7 NS
LDL cholesterol (mg/dl), mean  SD 106.4  37.2 120.4  45 NS
Triglycerides (mg/dl), median (IQR) 111 (50–380) 180.5 (49–615) 0.0001
TG/HDL-C ratio, median (IQR) 2.6 (1–18) 4.2 (0.7–228) 0.0001
IFG/diabetes, n (%) 6 (11) 10 (16) NS
ALT (U/l), median (IQR) 34.5 (7–188) 40.5 (7–280) NS
AST (U/l), median (IQR) 29 (13–281) 31 (11–229) NS
LS (kPa), median (IQR) 6.8 (3.2–48) 7 (3.3–33.8) NS
HIV-RNA <47 copies/ml, n (%) 29 (52) 45 (73) 0.03
CD4 count <200 cells/ml, n (%) 30 (54) 46 (74) 0.03
Basal CD4 count cells/ml, median (IQR) 429 (73–1208) 460 (35–1009) NS
Previous ART (years), median (IQR) 8.5 (0.1–18) 9 (0.33–21) NS
HAART exposure >1 year, n (%) 39 (70) 57 (92) 0.02
PI usea (n) 31b 48c NS
NNRTI usea (n) 17d 38b NS
NRTI non-d-drug usea (n) 32 50 NS
NRTI d-drug usea (n) 35b 51e NS
SD, standard deviation; NS, not signiﬁcant; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; IQR, interquartile range; TG/HDL-C ratio,
triglycerides to high-density lipoprotein cholesterol ratio; IFG, impaired fasting glucose; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LS, liver stiffness;
ART, antiretroviral therapy; HAART, highly active antiretroviral therapy; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside
reverse transcriptase inhibitor; d-drug, dideoxynucleosides.
a Exposure for >1 year.
b Data missing for three patients in the univariate analysis.
c Data missing for two patients in the univariate analysis.
d Data missing for ﬁve patients in the univariate analysis.
e Data missing for one patient in the univariate analysis.
Table 4
Presence of BL negative/BL positive ultrasound echo-pattern and associated variables in the two study groups
Variables HIV p-Value HIV/HCV p-Value
BL neg (n = 26) BL pos (n = 31) BL neg (n = 30) BL pos (n = 31)
Age (years), mean  SD 44.4  11.2 45.6  6.7 NS 44.0  6.1 45.9  4.1 NS
BMI (kg/m2), mean  SD 23.0  3.4 24.2  2.9 NS 22.5  2.4 23.5  3.4 NS
Alcohol use, n (%) 1 (4) 5 (16) NS 1 (3) 5 (16) NS
Lipodystrophy, n (%) 8 (31) 20 (65) 0.02 15 (50) 27 (87) 0.003
Metabolic syndrome, n (%) 3 (12) 13 (42) 0.02 2 (7) 10 (32) 0.03
Total cholesterol (mg/dl), mean  SD 187.5  34 224.1  53 0.003 156.2  38 178  42.7 0.04
HDL cholesterol (mg/dl), mean  SD 44.4  9.8 40.2  10.8 NS 45.1  17 42.65  16 NS
LDL cholesterol (mg/dl), mean  SD 121.5  36.3 142.1  42.2 NS 93.4  33.4 97.2  37.7 NS
Triglycerides (mg/dl), median (IQR) 120 (62–261) 193 (49–615) 0.002 103 (50–380) 127 (81–614) 0.02
TG/HDL-C ratio, median (IQR) 2.6 (1–6.1) 4.7 (0.7–22.8) 0.001 2 (1–18) 3 (1–20) 0.05
IFG/diabetes, n (%) 1 (4) 1 (3) NS 5 (17) 9 (29) NS
ALT (U/l), median (IQR) 20 (7–80) 29 (7–117) 0.04 50.5 (17–188) 51 (18–280) NS
AST (U/l), median (IQR) 21 (13–38) 25 (11–56) NS 40.5 (21–281) 45 (22–229) NS
LS (kPa), median (IQR) 5.6 (3.2–13.7) 6.2 (3.3–26.6) NS 9.7 (4.3–48.8) 9.8 (4.3–33.8) NS
HIV-RNA <47 copies/ml, n (%) 9 (35) 24 (77) 0.001 20 (67) 21 (68) NS
CD4 nadir <200 cells/ml, n (%) 10 (38) 23 (74) 0.01 20 (67) 23 (74) NS
Basal CD4 count, cells/ml, median (IQR) 438 (169–1093) 486 (35–964) NS 407 (73–1208) 444 (35–1009) NS
Previous ART (years), median (IQR) 5.5 (0.1–17) 8 (0.33–17) NS 10 (0.16–18) 10 (0.42–21) NS
HAART exposure >1 year, n (%) 15 (58) 28 (90) 0.01 24 (80) 29 (94) NS
PI usea (n) 11 22 NS 20b 26c NS
NNRTI usea (n) 10c 18 NS 7b 20b NS
NRTI d-drug usea (n) 14 25 NS 21b 26d NS
Genotype 3, n (%) - - - 9 (30) 10 (32) NS
BL, bright liver echo-pattern; HCV, hepatitis C virus; SD, standard deviation; NS, not signiﬁcant; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; IQR, interquartile range; TG/HDL-C ratio, triglycerides to high-density lipoprotein cholesterol ratio; IFG, impaired fasting glucose; ALT, alanine aminotransferase;
AST, aspartate aminotransferase; LS, liver stiffness; ART, antiretroviral therapy; HAART, highly active antiretroviral therapy; PI, protease inhibitor; NNRTI, non-nucleoside
reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; d-drug, dideoxynucleosides.
a Exposure for >1 year.
b Data missing for three patients in the univariate analysis.
c Data missing for two patients in the univariate analysis.
d Data missing for one patient in the univariate analysis.
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Figure 1. Correlation between hepatic ultrasound echo-pattern and liver stiffness in
the study population (N, normal homogeneous echo-pattern; BL, bright liver echo-
pattern; C, coarse echo-pattern; CN, coarse nodular echo-pattern). Hepatic
ultrasound echo-pattern was signiﬁcantly correlated with liver stiffness
(rho = 0.24; p < 0.02).
V. Li Vecchi et al. / International Journal of Infectious Diseases 16 (2012) e397–e402 e401(OR) 1.1, 95% conﬁdence interval (CI) 1.05–1.3, p < 0.02) and
Framingham risk score (b = 1.4; OR 4.3, 95% CI 1.1–17.7, p < 0.05)
were independently associated with BL on multiple logistic
regression analysis.
4. Discussion
The present study shows that the prevalence of HS, assessed by
US, is high in both HIV mono-infected and HIV/HCV co-infected
patients (54% and 51%, respectively). At present, data on the
prevalence and risk factors of HS in HIV mono-infected patients are
limited. In some studies, histological non-alcoholic steatohepatitis
has been diagnosed only in patients who have undergone liver
biopsy due to unexplained transaminase elevation or lipodystro-
phy.8,29,30 To our knowledge, only three US-based studies on HS
prevalence in HIV patients have been published. In one study, HS
prevalence was 31%,31 while a lower HS prevalence (13%) was
found by Lesi et al.32 in an HIV-positive African cohort and by Ryan
et al.33 in patients with only severe HS. The lower HS prevalence
found in these former studies compared to our results may be due
to the enrollment of Afro-American patients, who have been
reported as having a lower HS prevalence in comparison with
Caucasians, as well as the exclusion of patients with signiﬁcant
alcohol consumption.31
Several factors were found to be associated with HS in our HIV
mono-infected and co-infected patients in the univariate analysis.
Biochemical abnormalities, such as high total cholesterol and
triglyceride values and metabolic syndrome were found in patients
with HS.9,31,34 As regards other metabolic factors, mean BMI was
relatively low, as is frequently observed in HIV patients, and was
not associated with HS.30 Among the HIV-related factors,
undetectable HIV-RNA was associated with HS in the mono-
infected patients. As previously hypothesized,35,36 it appears that
undetectable HIV-RNA is a surrogate for HAART use. CD4+ nadir
below 200 cells/ml was also associated with HS in our HIV mono-
infected patients, only on univariate analysis. Discrepant data are
reported in the literature on the relationship between immune
status assessed by CD4+ cell count and HS;9 nevertheless a recent
study on the natural history of HS in co-infected patients showed
that high CD4+ levels were associated with less progression of
HS.37
Likewise, as regards the associations found between most of the
described metabolic abnormalities and HS, there was a signiﬁcant
relationship only on univariate analysis between HS and HAART
exposure for more than 1 year in both the total HIV population and
the HIV mono-infected patients. As regards the lack of a signiﬁcantassociation between BL and exposure for more than 1 year to single
classes of antiretroviral drugs, the small number of patients could
have played a crucial role.
In a recent meta-analysis,9 only one out of eight studies
evaluating PIs, NRTIs, and NNRTIs in co-infected patients showed a
weak association between PI use and HS, and only McGovern
et al.35 found an association between NRTI use and HS. Guaraldi
et al.12 showed that cumulative NRTI exposure was an indepen-
dent predictor of NAFLD. In this regard, lipodystrophy syndrome,
which affects 40–50% of HIV patients under HAART and is often
linked to insulin resistance, hypertriglyceridemia, low HDL levels,
and metabolic syndrome, was associated with HS in both HIV
mono-infected and co-infected patients.8,38,39 In our HIV popula-
tion, indirect signs of HAART-related effects such as lipodystrophy,
higher triglycerides, total cholesterol levels, and undetectable HIV-
RNA appear to corroborate the relationship between HAART
exposure and HS. However, further studies are needed to conﬁrm
the role of HAART in HS pathogenesis and its natural history.
Ideally HS would be assessed by liver biopsy, but because of its
invasiveness and risks this may be considered unethical for
asymptomatic HIV mono-infected patients. In addition, ultraso-
nography has demonstrated a higher sensitivity in the detection of
HS in patients without known liver disease and obesity,26,40 as was
the case for our HIV mono-infected patients with low BMI.
However, the sensitivity of US in the diagnosis of HS is lower when
infection with HCV genotype 1–2 occurs. This may explain in part
the higher, even if not signiﬁcant, HS prevalence found in HIV
mono-infected compared with HCV co-infected patients. Never-
theless, the reduced need for liver biopsy in particular among co-
infected patients with HCV genotype 2–3, due to the urgency of
beginning and the better response to antiviral treatment, has
encouraged the use of non-invasive methods in the assessment of
both HS and ﬁbrosis. In this regard, the prevalence of HS in co-
infection is in agreement with what has been reported in other
studies.9 No association with HCV factors such as HCV genotype or
viral load was found, and this may be due to the small percentage
of patients infected with genotype 3. Another limitation of
ultrasonography is its inability to distinguish simple HS from
steatohepatitis.
Transient elastography has already been validated for the
measurement of liver ﬁbrosis in HIV and HCV seropositive
patients.28,41 Currently, this has been demonstrated to be a
reliable tool in the non-invasive assessment of ﬁbrosis, especially
at the advanced stages in histological non-alcoholic steatohepatitis
patients,42 although in co-infected patients ﬁbrosis may be
overestimated by the presence of HS.43 Nevertheless we did not
ﬁnd an association between BL and ﬁbrosis or severity of BL and
advanced liver ﬁbrosis (measured as LS), in either HIV group. In this
regard, Woreta et al.37 recently showed that the majority of HIV/
HCV co-infected patients (most of whom were black and had HCV
genotype 1) had no HS or trivial HS, and compared with patients
with signiﬁcant HS, a signiﬁcant difference in liver ﬁbrosis was not
found. Interestingly they showed there was no progression of HS in
most patients.
On multiple logistic regression analysis, the only variables
associated with HS without advanced liver ﬁbrosis in the total HIV
patients were both triglyceride levels and Framingham risk score.
Several studies have reported the association of NAFLD with
multiple CVD risk factors, including metabolic syndrome and
insulin resistance.11 The biological mechanisms by which NAFLD
may contribute to a higher risk of CVD are not fully understood.
Ectopic fat deposition, of which HAART-lipodystrophy is an
expression, may play a leading role in the development of insulin
resistance, inﬂammation, and NAFLD, and may be a source of
multiple factors implicated in atherogenesis.44 Calza et al.45
recently showed that a longer exposure to ART and a diagnosis
V. Li Vecchi et al. / International Journal of Infectious Diseases 16 (2012) e397–e402e402of lipodystrophy syndrome were signiﬁcantly associated with
metabolic syndrome and diabetes, which confers an increased risk
of CVD. Since in our HIV patients HS and CVD shared several risk
factors (hypertriglyceridemia, HAART-lipodystrophy, metabolic
syndrome, TG/HDL-C ratio, and total cholesterol), we suppose that
HS should also be considered an early marker of CVD. These
ﬁndings support the use of appropriate measures for maintaining
triglycerides within the normal range in order to prevent both fatty
liver and CVD in HIV patients. In addition, we suggest that in our
HIV population with HS, the burden of CVD risk is greater than that
of liver disease progression. Further studies are needed to evaluate
the role of HS as an independent CVD risk factor in this population.
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